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Background: Protease Inhibitors (PIs) are the second- and last-line therapy for the majority of 
HIV-infected patients worldwide. Only around 20% of individuals who fail PI regimens 
develop major resistance mutations in protease.  We sought to explore the role of mutations 
in gag-protease genotypic and phenotypic changes within six Nigerian patients who failed 
PI-based regimens without known drug resistance associated protease mutations in order to 
identify novel determinants of PI resistance. 
 
Methods: Target enrichment and NGS by Illumina Miseq were followed by haplotype 
reconstruction. Full length gag-protease regions were amplified from baseline (pre-PI) and 
virologic failure (VF) samples, sequenced and used to construct gag/protease pseudotyped 
viruses.  Phylogenetic analysis was performed using maximum likelihood methods. 
Susceptibility to lopinavir (LPV) and darunavir (DRV) were measured using a single-cycle 
replication assay. Western blotting was used to analyse Gag cleavage. 
Results: In one of six participants (subtype CRF02_AG) we found 4-fold lower LPV 
susceptibility in viral clones during failure of second line treatment. A combination of four 
mutations (S126del, H127del, T122A and G123E) in p17 matrix of baseline virus generated a 
similar 4x decrease in susceptibility to LPV but not darunavir. These four amino acid changes 
were also able to confer LPV resistance to a subtype B gag-protease backbone. Western 
blotting did not demonstrate significant Gag cleavage differences between sensitive and 
resistant isolates. Resistant viruses had around 2-fold lower infectivity compared to sensitive 
clones in the absence of drug. NGS combined with haplotype reconstruction revealed 
resistant, less fit clones emerged from a minority population at baseline and thereafter 
persisted alongside sensitive fitter viruses. 
Conclusions: We have used a multi-pronged genotypic and phenotypic approach to document 
emergence and temporal dynamics of a novel protease inhibitor resistance signature in HIV-1 
matrix, revealing the interplay between Gag associated resistance and fitness. 
Introduction 
As global scale up of antiretroviral therapy (ART) progresses in the absence of universal viral 
load monitoring, significant numbers of persons living with HIV (PLWH) are experiencing 
virological failure (VF) with emergent drug resistance(1-3). In addition, pre-treatment drug 
resistance (PDR) has been rising over the past decade(4-6). Although integrase inhibitors are 
now recommended by WHO in regions where PDR exceeds 10%(7, 8), second line ART in 
low and middle-income countries (LMIC) is likely to remain dependent on boosted protease 
inhibitors (PI), specifically lopinavir/ritonavir or atazanavir/ ritonavir.  
 
Studies demonstrate that the detection of major canonical protease mutations(9) is around 
20% in PLWH treated with PI containing combination ART(10, 11), raising the question of 
how virologic failure occurs in the remaining cases. Inadequate adherence to medication has 
been implicated(12-14), and the contribution of minor protease mutations explored(15). 
Determinants of susceptibility outside the protease gene have also been considered(16). 
Interestingly, although PI monotherapy can be effective in some populations in clinical 
practice (17), this is associated with a higher prevalence of major PI resistance mutations at 
VF as compared to PI combined with 2 two nucleoside reverse transcriptase inhibitors 
(NRTI)(18, 19).  
 
The HIV-1 envelope (Env) has been reported in two studies to impact PI susceptibility (20, 
21), with a number of reports of diverse env sequence changes during PI failure(22, 23).  Gag 
is highly polymorphic across HIV-1 subtypes, and existing literature reports diverse 
mutations occurring both within and outside cleavage sites following treatment with older PI 
such as indinavir, saquinavir and nelfinavir in subtype B infections (16, 22-26). Although 
there has been very limited evidence on the role of HIV-1 gag in susceptibility to modern 
boosted protease inhibitors such as lopinavir/ritonavir used in second line ART in non-B 
subtypes, we and others have reported that around 1 in 6 individuals infected with non-
subtype B HIV who fail modern PI have Gag encoded reduced phenotypic susceptibility to 
PI(27-31), though specific amino acid determinants have remained elusive.  
 
Cleavage site mutations are thought to partially restore efficient cleavage by protease in the 
presence of bound drug(32, 33). The mechanism for non-cleavage site mutations may include 
allosteric changes in protease-gag interactions that influence the efficiency by which protease 
locates cleavage sites through dynamic intermolecular interactions in the presence of 
drug(34, 35). For example, our group previously reported the emergence of T81A in Gag that 
appeared to correlate with reduced susceptibility to the modern PI lopinavir in a subtype AG 
infected individual in France(28). This mutation was predicted to impact intermolecular 
interactions between Gag and protease by Deshmukh and colleagues using nuclear magnetic 
resonance (NMR)(35).  
 
Here we sought to explore the role of mutations in gag encoded determinants of reduced PI 
susceptibility in non-subtype B HIV-1 and to elucidate their evolution in people living with 




We identified six individuals on second line, protease inhibitor based ART who experienced 
virological failure without major protease mutations from a PEPFAR funded treatment cohort 
in Nigeria and who had samples collected on at least two time-points (pre second-line 
initiation and following second-line virologic failure). Having previously reported that 
baseline phenotypic susceptibility was not associated with subsequent virologic ‘failure’ (36) 
in this cohort, here we sought to explore changes over time in phenotypic susceptibility that 
could be associated with changes in HIV-1 gag-protease 
 
Next generation sequencing 
Manual nucleic acid extraction was done using the QIAamp Viral RNA mini kit, Qiagen 
(Hilden, Germany) with a plasma input volume of 0.5-1.5 mL. The first strand of cDNA was 
synthesised using SuperScript IV reverse transcriptase, Invitrogen, (Waltham, MA, USA), 
followed by NEBNext second strand cDNA synthesis E6111, New England Biolabs GmbH, 
(Frankfurt, Germany). Sample libraries were prepared as per the SureSelectXT automated 
target enrichment protocol, Agilent Technologies (Santa Clara, CA, USA) with in-house HIV 
baits. Whole genome deep sequencing was performed using Illumina Miseq platform (San 
Diego, CA, USA). Trimmed reads were then compared to a reference panel of 170 HIV 
subtypes/CRFs from the Los Alamos database (https://www.hiv.lanl.gov) and the best match 
was used for reference mapping. Duplicate reads were removed from the BAM files and a 
consensus sequence was generated using a 50% threshold. Mutations were included if they 
were present at over 2% frequency within the read mixture at that position, with a minimum 
read depth of 100. An in-house custom script was used to identify SNPs at each position by 
BLAST analysis of individual HIV pol against the HXB2 reference genome.  
 
Haplotype Reconstruction and Phylogenetics:  
Whole-genome haplotype reconstruction was performed using a newly developed maximum-
likelihood method, HaROLD (Haplotype assignment of virus NGS data using co-variation of 
variant frequencies, Richard A. Goldstein, Asif U. Tamuri, Sunando Roy, Judith Breuer 
bioRxiv 444877; doi: https://doi.org/10.1101/444877). SNPs were assigned to each haplotype 
so that the frequency of a variant at any time point was represented by the sum of the 
frequencies of the haplotypes containing that variant. Time-dependent frequencies for 
longitudinal haplotypes were optimised by maximizing the log likelihood, which was 
calculated by summing over all possible assignments of variants to haplotypes. Haplotypes 
were then reconstructed based on posterior probabilities. The calculations were repeated with 
a range of possible haplotype numbers and the optimal number of haplotypes was determined 
by the resulting value of the log-likelihood. After constructing haplotypes, a refinement 
process remapped reads from BAM files to the constructed haplotypes. Haplotypes were also 
combined or divided according to AIC scores, in order to give the most accurate 
representation of viral populations. Phylogenetic trees of constructed haplotypes were 
constructed using RAxML-NG using the GTR model and 1000 bootstraps. 
 
Coreceptor usage  
CCR5 / CXCR4 usage was predicted using env sequences with the online tools Geno2Pheno 
(https://www.geno2pheno.org) and WebPSSM 
(https://indra.mullins.microbiol.washington.edu/webpssm/).  
 
Amplification of full-length gag-protease genes 
We amplified from plasma taken before PI initiation and from a failure time point for each 
individual. NGS was used to obtain a consensus whole genome sequence for each of the 12 
samples. Full length gag- protease sequences were obtained from plasma by standard PCR: 
HIV-1 RNA was extracted from plasma samples using the QIAamp viral RNA extraction kit. 
Using previously described techniques,(37, 38) full-length gag-protease was amplified and 
cloned into a subtype B-based (p8.9NSX+) vector. Clonal sequencing of up to 10 plasmids 
was performed by standard Sanger sequencing. The variant that most closely represented the 
next-generation sequencing derived consensus, was taken forward for phenotypic testing. 
Sequences were manually analysed using DNA dynamo software 
(http://www.bluetractorsoftware.co.uk) software. Protease sequences were analysed for PI 
resistance mutations using the Stanford Resistance Database (https://hivdb.stanford.edu). 
Phylogenetic analysis was performed using maximum likelihood methods in MEGA v7.0 
(39) Bootstrapping was performed as previously described(28). 
 
Site directed mutagenesis 
Site directed mutagenesis was carried out using Quick ChangeTM (Stratagene) according to 
manufacturer instructions. Mutagenesis was verified by Sanger sequencing. 
 
PI susceptibility and infectivity assays 
PI susceptibility and viral infectivity were determined using a previously described single 
assay. Briefly, 293T cells were co-transfected with a Gag-Pol protein expression vector 
(p8.9NSX) containing cloned patient-derived full-length gag-protease sequences, pMDG 
expressing vesicular stomatitis virus envelope glycoprotein (VSV-g), and pCSFLW 
(expressing the firefly luciferase reporter gene with the HIV-1 packaging signal) as 
previously described. PI drug susceptibility testing was carried out as previously 
described(37). Transfected cells were seeded with serial dilutions of lopinavir and harvested 
pseudovirions were used to infect fresh 293T cells. To determine strain infectivity, virus was 
produced in the absence of drug. 
Infectivity was monitored by measuring luciferase activity 48 h after infection. Results 
derived from at least two independent experiments (each in duplicate) were analysed. The 
IC50 was calculated using GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA, USA). 
Susceptibility was expressed as a fold change in IC50 as compared to the subtype B reference 
plasmid p8.9NSX. Replicative capacity of these viruses was assessed by comparing the 
luciferase activity of recombinant virus with that of the WT subtype B control virus in the 
absence of drug. Equal amounts of input plasmid DNA were used, and it has previously been 
shown that percentage infectivity correlates well with infectivity/ng p24 in this system(37). 
Differences in PI susceptibility were compared with the paired t test.  
 
Multi round infectivity assay 
WT (R9-BaL) and Mutant (R9-BaL with the 5 amino acid changes in MA) virus prep was 
used to infect 1.5x106 of SupT1-CCR5 suspension cells in 2mL of media per well and 
incubated at 37oC for 2 hours, followed by low centrifugation (800xg) for 10 minutes. The 
supernatant was discarded, the cell pellets resuspended in RPMI media and used to infect 
4x106 SupT1-CCR5 cells. Infectious virion supernatant was harvested on days 2, 4, 7, 9 and 
11. The harvested virion supernatant was used to infect fresh TZMbl cells to assay for 
infectivity which was based on the Tat-dependent upregulation of LTR-driven firefly 
luciferase expression upon HIV-1 infection of TZMbl cells. Luciferase Assay Reagent was 
added, and the luminescence was measured using GloMax 96 Microplate Luminometer 
(Promega). 
 
The PI drugs used in this study were obtained from the AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH. 
 
Western Blot Analysis 
Using a previously described method(40), equal amounts of each of the viral clone plasmid 
was used to transfect 293T cells, in addition to a VSV-G plasmid and reporter genome 
expressing plasmid.  Each of the pseudovirions was produced in the absence and presence of 
a range of concentrations of LPV, added 16 hours following transfection.  
Forty-eight (48) hours post transfection with the plasmid preparations, the culture supernatant 
was harvested and passed through a 0.45-m pore-size filter to remove cellular debris. The 
filtrate was centrifuged at 14,000rpm for 90 minutes to pellet virions. The pelleted virions 
were lysed in Laemmli reducing buffer (1M Tris-HCl pH 6.8, SDS, 100% glycerol, β-
mercaptoethanol and bromophenol Blue). Cell lysates were subjected to electrophoresis on 
SDS, 4–12% Bis-Tris Protein Gels (Thermo Fisher Scientific) under reducing conditions. 
This was followed by electroblotting onto PVDF membranes. The HIV-1 Gag proteins were 
visualized by a trans-Illuminator (Alpha Innotech) using anti-p24 Gag antibody. 
 
Ethics 
Informed consent was obtained from all participants and ethics approval for virological 
testing was obtained from the Nigeria National Research Ethics Committee of Nigeria 




Phenotypic drug susceptibility following PI failure 
Participant characteristics of the six HIV-infected individuals failing PI based second line 
ART are shown in figure Table 1. Three were infected with CRF02_AG recombinant strain 
and three with subtype G HIV strains. NGS of gag and pol was used to generate consensus 
sequences for the six patients at two time points – before PI treatment (baseline) and at 
virologic failure (VF). A significant number of amino acid changes occurred between time 
points in each individual, with most occurring in the matrix (p17) domain of Gag. Phenotypic 
PI susceptibility testing was performed on plasma derived clones obtained at the same time 
points. 
 
Participant 6 had a significant difference in PI susceptibility between baseline and failure 
time points (Figure 1 and supplementary figure 1). At VF, the LPV IC50, expressed as fold 
change (FC) compared to the subtype B reference was 20.3 compared to 5.2 prior to initiation 
of LPV treatment. We phenotyped four clones from baseline, all with similar LPV 
susceptibility. Baseline genotype (pre PI) indicated that the individual had developed 
extensive resistance to first line ART with nucleoside reverse transcriptase inhibitor (NRTI) 
mutations K65R, M184I conferring high level tenofovir and lamivudine resistance 
respectively, as well as K103N and Y181C conferring to non-nucleoside reverse transcriptase 
inhibitors (NNRTI). The co-occurrence of the latter two non-NRTI mutations suggests that 
the individual may have been pre-treated with first line ART containing nevirapine, or have 
received single dose nevirapine for prevention of mother to child transmission(41).  
 
We further explored this participant in order to elucidate determinants of resistance. 
Sequence alignment of full length gag and protease genes from sensitive and resistant clones 
revealed: 19 amino acid changes in matrix (MA), one change in each of capsid (CA), p2 and 
nucleocapsid (NC) as well as an insertion of four amino acids (E, L, R and E) in the p6 region 
of the resistant clone from gag position 477 (Figure 1). In protease, there was an M46V 
mutation in the resistant virus that was found to have no impact on LPV susceptibility 
(Supplementary figure 2).  
 
Interestingly, the VF sample was taken 64 months after PI initiation when the viral load was 
66,277 copies/ml, and within this plasma sample two distinct virus clones were isolated 
(Figure 1, hatched and black bars). There was a 4-5 fold difference in LPV susceptibility 
between the two clones, suggesting a mixture of susceptible and ‘resistant’ viruses at the 
failure time point (Figure 1). We proceeded to map determinants of susceptibility using these 
two clones identified at failure. First, we sought to determine the role of a four amino acid 
insertion in the p6 domain. Using standard site directed mutagenesis techniques, amino acids 
E, L, R and E were inserted into a susceptible clone at position 477 in the p6 domain 
(Supplementary figure 3). Conversely, E, L, R and E residues were deleted in the less 
susceptible clone from the same location. There was no significant change in susceptibility to 
LPV as a result of the ELRE insertion (Supplementary figure 3). 
 
Matrix deletion of S126 and H127 confer reductions in LPV susceptibility 
Given that the greatest number of changes occurred in the MA region, we sought to explore a 
possible role for MA amino acid changes on PI susceptibility. First, sequence changes 
occurring near the MA/CA cleavage site (within 10 amino acids) were considered. We noted 
that the more resistant virus had a deletion of Gag positions 126 and 127 as well as adjacent 
T122A and G123E mutations. Using site directed mutagenesis, serine (Gag position 126) and 
histidine (Gag position 127) residues were deleted in susceptible clone. Conversely, serine 
and histidine residues were inserted in the less susceptible clone. Deletion of Ser 126 and His 
127 in the susceptible virus, led to a significant decrease in LPV susceptibility for the mutant 
virus (Figure 2). Conversely, the insertion of Ser and His residues in the resistant virus 
increased susceptibility of the mutant (Figure 2). However, the changes at positions 126 and 
127 did not completely account for the differences in LPV susceptibility.  
 
The matrix deletions at S126 and H127 act synergistically with T122A and G123E gag  
A combination of S126del, H127del and T122A, G123E mutations in the susceptible virus 
led to a 4x decrease in susceptibility to LPV (FC IC50 from 5.3 to 22.7), figure 2 and 
supplementary table 2. Conversely, S126Ins, H127Ins and A122T, E123G in the LPV 
resistant virus, led to a three-fold decrease in resistance as shown in Figure 2. We also tested 
the effect of the four amino acid signature on susceptibility to the second generation PI 
darunavir (DRV), and found no significant impact (Supplementary figure 4). 
 
We sought to establish the effect of each of the four amino acid changes occurring alone. 
Using the resistant viral clone, four different mutant viruses were created with single amino 
acid changes at Gag: A122T, E123G, S126ins and H127ins. Results of the phenotypic drug 
susceptibility testing of these mutants showed that only E123G appeared to increase 
susceptibility (supplementary figure 5), and the combination of four amino acids had the 
greatest impact on LPV susceptibility. 
We next tested whether the four amino acid signature T122A/ G123E/ S126del/ H127del 
could confer LPV resistance in a different subtype context. We chose the reference p8.9NSX 
subtype B virus and made the amino acid deletions at Gag positions 126 and 127 as well as 
the adjacent T122A and G123E mutations. In addition, we added a V128 deletion given that 
subtype CRF02_AG consensus contains this deletion as compared to subtype B. The five 
mutations (T122A/ G123E/ S126del/ H127del/V128del) reduced susceptibility to LPV by 
more than 3-fold, indicating that they are effective in a divergent subtype (Figure 3). 
 
Matrix/Capsid (p17-p24) cleavage and differential PI susceptibility  
We hypothesized that the efficiency of MA/CA cleavage of HIV-1 polyproteins would differ 
between the susceptible and resistant clones in the presence of LPV. To test this hypothesis, 
we employed western blot analysis. Gag cleavage patterns were examined using the 
supernatants and cellular extracts of 293T cells transfected with each plasmid in the presence 
and absence of increasing concentrations of LPV (Figure 4). We probed with a polyclonal 
p24 antibody and as expected there was incomplete cleavage of p24-p2 at higher LPV doses 
in both virus containing supernatants and the cell extracts, consistent with previous data(32). 
We calculated ratios of p24/p41 to specifically probe the p17/p24 cleavage site in the vicinity 
of the four amino acid signature. We found that the resistant virus cleaved p17/p24 more 
efficiently in the absence of drug and up to 30nM of LPV.  
 
The resistance signature arises from a minority viral population detected at baseline 
We proceeded to ask the question of when resistance emerged. Given the lengthy time period 
of over 5 years between the two samples we ideally needed a sample from an intermediate 
time point. We were able to identify a plasma sample on second line from 41 months, with 
VL of 241, 894. We refer to the 41-month time point as VF1 and the original 64-month time 
point as VF2. NGS analysis at whole genome level was undertaken for all 3 time points and 
table 2 shows variant frequencies at sites in Gag and Pol associated with drug exposure. Of 
note we observed loss of mutations to lamivudine (M184I), tenofovir (K65R) and efavirenz 
(K103N) between baseline and VF1. The individual was prescribed lamivudine, zidovudine 
and lopinavir/ritonavir for second line and the resistance data indicate lack of drug pressure 
from lamivudine.  
 
The NGS showed that T122A/ G123E were present at low abundance before initiation of PI 
(approx. 5% of reads, table 2). The proportion of T122A/ G123E increased at VF1 to 13%. 
These mutations were observed at increased frequency at VF2 both by target enriched NGS 
and also direct gagpro PCR from plasma, but NGS also showed emergence of lamivudine 
resistance mutant M184V, suggesting improved adherence to lamivudine between VF1 and 
VF2.  
 
We next generated whole genome haplotypes for each time point using NGS data in order to 
firstly establish the phylogenetic relationships between viruses with differing PI resistance 
associated mutations, and also to determine the co-receptor usage of virus haplotypes as this 
might provide clues as to origins of virus variants (Figure 5). All inferred haplotypes were 
predicted to use CCR5 with FPR of <5%, and no CXCR4 using viruses were predicted in 
either of the two algorithms used.  
 
We proceeded to clone sequences from plasma at VF1 in addition to those previously cloned 
from VF2 and inferred phylogenetic trees. None of the four gagpro clones from baseline 
(before initiation of PI) contained any of the four amino acid changes T122A/ G123E/ 
S126del/ H127del, consistent with NGS data showing these variants were present at 
<5%(table 2).  Clones from the intermediate time point VF1 clustered with the VF2 clones 
rather than with the baseline clones (Figure 6). Overall, there was excellent concordance 
between the inferred whole genome haplotypes and gagpro clones, though there appeared to 
be greater diversity in haplotypes. In vitro phenotypic drug susceptibility of cloned sequences 
revealed both sensitive and resistant viruses at VF1 as well as VF2 (Figure 6), with the 
resistant clones from VF1 and VF2 clustering together and sharing the 4 amino acid 
resistance associated signature S126del, H127del and T122A, G123E. As expected, the 
susceptible clones from VF1 and VF2 time points also clustered with each other in a distinct 
part of the tree.  
 
Persistence of both resistant and susceptible viruses can be explained by replication 
capacity 
A surrogate for fitness in our assay is single round infectivity (measured in RLU) in the 
absence of drug, which is given a value of 100% for our reference subtype B virus. We 
measured the single round infectivity (replication capacity, RC) of clones bearing patient 
derived gag-protease sequences from each time point. Interestingly, resistant clones had a 
lower RC than susceptible viruses (around 1.5 fold), regardless of whether they were isolated 
from VF1 or VF2 (Figure 7). We also tested full length replication competent virus bearing 
the 4 amino acid signature with the wild type over multiple rounds of replication and found a 
similar difference in RC (Figure 7). The mixture of sensitive and resistant strains is consistent 
with incomplete drug adherence and therefore variable drug pressure, or alternatively with 




Based on NMR and X ray crystallography studies, p17 comprises five major alpha helices 
connected primarily by short loops(35, 42). The C terminus of matrix is predicted to be 
disordered, which has hampered efforts to characterise the structural characteristics of this 
region. One study suggested that deletions at 125 and 126 would stabilise p17(43), indicating 
that despite disorder, changes in the region might lead to significant changes in stability and 
therefore possibly altered effects of protease inhibition on cleavage. 
 
In this study on CRF02_AG and subtype G clinical isolates from a Nigerian cohort, we 
demonstrated the role of p17 amino acid mutations occurring near the p17/p24 cleavage site 
in contributing to PI resistance. The double deletion of ser and his at Gag 126 and 127 
respectively had a modest impact on in-vitro phenotypic PI-susceptibility. When this deletion 
occurred together alongside T122A and G123E, we observed a 4-5 fold decrease in 
susceptibility to lopinavir. The four mutation combination was also able to confer similar 
resistance to a subtype B virus, indicating that it may emerge across subtypes.  
 
We aimed to understand the mechanism at play in the T122A, G123E, S126del, H127del 
phenotype. Western blotting of virus containing supernatants from producer cells revealed 
significant differences in cleavage without drug at the p17-p24 cleavage site, with the 
resistant clone demonstrating more efficient cleavage. In the presence of drug, Gag cleavage 
at the MA/CA cleavage site (as obtained from p24/p41 ratios) was also more efficient in the 
resistant viral clone. Therefore, rescue of infectivity in the presence of drug in vivo might be 
explained by inherently more efficient or kinetically favourable cleavage.   
 
G123E was reported to arise when viruses were propagated with investigational protease 
inhibitors KNI-272 and UIC-94003(44). Gag G123E was found to potentially interact with 
protease by NMR (35), providing a potential mechanism for its effect. This was more 
recently corroborated by Samsudin and colleagues(45), using multiscale modelling and 
simulations to reveal how non-cleavage site mutations can directly interact with cleavage site 
residues to affect their local environment. Through the use of contact analysis between the 
MA/CA cleavage site residues and gag position 123 in a WT (G123) and mutant (E123) 
proteins, the residue at position 123 was shown to make contact primarily with the N-
terminal portion of the cleavage site from the same Gag subunit. Both WT (glycine) and 
mutant (glutamate) residues showed a similar percentage of contact over the course of the 
simulations.  When the CG simulations were “back-mapped” and transformed into atomic 
resolution, atomistic simulations of a single MA-CA-SP1 sub-unit showed that glutamate 
(mutant) residue at position 123, but not glycine (wild ty,pe) interacted primarily with the 
cleavage site Y132 and also contacted residues N131 and Q130. Given the change in the 
overall size and charge of the residue in the WT and mutants (from small and neutral to large 
and acidic), the G123E mutation alters the accessibility and electrostatic properties in the 
vicinity of the cleavage site and therefore was expected to directly interfere with proteolysis. 
Although our present study implicates G123E in reduced PI susceptibility, we show here that 
the combination of mutations that was observed in the patient was needed for maximal effect.  
 
We next used NGS to explore the dynamics of emergence of Gag amino acid changes during 
ongoing viremia under PI treatment. We were able to detect both T122A and G123 at low 
abundance at baseline, prior to PI exposure. Importantly, PCR from plasma RNA using 
gagpro specific primers did not amplify any sequences with these changes at baseline, 
highlighting an important contribution of NGS to the study of drug resistance. Whole genome 
reconstruction enabled us to infer phylogenetic trees and confirm findings that resistance 
conferring mutations occurred at both time points in phylogenetically related sequences. All 
virus haplotypes were predicted to be CCR5 using and therefore sensitive to the CCR5 
antagonist maraviroc. Intriguingly we found that resistant viruses had lower replication 
efficiency than wild type both in single and multi-round infections when there was no drug 
present. These experiments support a model where the composition of viral quasispecies 
under non suppressive ART depends on drug levels and inherent differences in replication 
dynamics conferred by relatively small numbers of amino acids.   
 
Our study has provided further evidence on the role of Gag in resistance to protease 
inhibitors. Given that failure to protease inhibitors arose with no major mutations in protease, 
the Gag protein itself could be a target for the development of future therapeutics. Presently, 
there are no FDA-approved ARVs that target HIV-1 Gag. A number of studies have 
attempted to establish Gag as a target. The design and development of drugs that target Gag 
could be approached in four broad ways as reviewed by Chinh Su and colleagues (46).  The 
first approach would involve screening and targeting of druggable allosteric sites present in 
Gag. A second approach is the identification of novel Gag mutations and using models to 
pre-emptively design Gag inhibitors. The third approach is the use of synergestic drugs to 
target multiple sites by chemically joining different potential Gag inhibitors to function as 
dual/triple inhibitors. The fourth approach is to design inhibitors to disrupt the 
conformational transition of Gag during viral maturation(46).  
 
The novel amino acid signatures that arose in vivo during treatment in this present study 
occurred in the matrix domain, and at non-cleavage site of Gag. The matrix (MA) domain of 
HIV-1 Gag plays critical roles in virus assembly by targeting the Gag precursor to the plasma 
membrane and directing the incorporation of the viral envelope (Env) glycoprotein into 
virions(47). A class of negatively charged lipids known as phosphoinositides such as 
Phosphatidylinositol-(4,5)-bisphosphate PI (4,5)P2  plays an important role in the association 
of HIV-1 Gag with the plasma membrane. To target the MA of Gag, small molecules could 
be synthesized to either binds to the [PI(4,5)P2]-binding cleft thereby competing for an MA- 
P1(4,5)P2 association or target the hydrophobic groove in the globular core matrix which 
would then dysregulate the myristyl switch mechanism, block the association of Gag with the 
cell membrane thereby disrupting virus assembly and release(48). This mechanism could 
have been involved in the reduction in susceptibility by our four amino acid resistance 
signature in matrix. The use of a small-molecule approach was also adopted by Ales Machara 
et al. and led to the identification of two arylquinazolines which inhibited HIV-1 capsid 
assembly by binding to the C-terminal domain of capsid and blocking viral replication(49). 
Additionally, inhibitors could be synthesised to destabilize Gag assembly hence slowing 
down the viral maturation process(46). 
 
In future work it would be interesting and important to know whether Gag mutations are 
capable of facilitating emergence of major protease mutations in prolonged culture conditions 
under suboptimal drug pressure. This could potentially explain why prevalence of major 
protease mutations increases over time during PI exposure in clinical studies(50). Next one 
could perform population dynamics simulations to incorporate RC and susceptibility data in 
order to model the proportion of resistant and susceptible viruses over time, and possibly 
therefore predict emergence of major mutations in protease.   
 
Our data are limited by the small sample size, lack of availability of plasma drug level 
measurements, and by the use of standard clonal approaches as opposed to single genome 
sequencing and amplification. This meant that we were not able to assess the contribution of 
minority variant populations on susceptibility. Some experiments were done in duplicate 
rather than triplicate. Nonetheless, we hypothesise that the four amino acid HIV-1 Gag 
signature is a contributory factor in PI failure in this PLWH from Nigeria.  
 
As we move towards next generation sequencing, this work highlights the limitations of 
current genotyping methods to infer PI susceptibility, and supports sequencing outside 
protease in to broaden the evidence base for the clinical management of patients who 
experience VF on PIs without major protease mutations. The work may ultimately also help 
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Table 1: phenotypic drug susceptibility  to lopinavir of 12 virus isolates at different time points. 
Patient 6 showed a significant difference in susceptibility between baseline and failure viruses.
























































Table 2: NGS variant derived data for three time points during LPV treatment showing the % 
of reads encoding resistance associated mutations in RT and Gag mutations known to be 






Fig 1: Variation in phenotypic PI susceptibility of full-length Gag-protease from HIV-1 
infected patient at different time points 
(A) is the sequences of the viral clones showing the amino acid changes in the MA, CA, P2, 
NC, p1 and p6 regions of gag between baseline (pre-PI treatment) and Viral failure (during PI 
treatment) timepoints. (B) Full-length Gag-protease was amplified from plasma samples and 
cloned into p8.9NSX+. VSV-g pseudotyped viruses encoding luciferase were produced by 
co-transfection in 293T cells. PI susceptibility of pseudovirions derived from each patient 
was determined using a single replication-cycle drug susceptibility assay as measured by 
luciferase activity. Data displayed are fold difference in IC50 values of LPV in comparison to 
that of the assay reference strain, p8.9NSX. Error bars represent the standard error of the 
mean of at least three independent experiments performed in duplicate. 
 
Fig 2: Gag 126del and 127del mutations occurring with T122A and G123E confers 
resistance to the protease inhibitor lopinivir in the absence of any major protease 
mutations  
(A) sequences of the viral clones showing the amino acid changes (in red) introduced using 
standard site directed mutagenesis techniques. (B) and (C) Full-length Gag-protease with 
indicated mutations was amplified from plasma samples and cloned into p8.9NSX+. VSV-g 
pseudotyped viruses encoding luciferase were produced by co-transfection in 293T cells. PI 
susceptibility of pseudovirions derived from each patient was determined using a single 









Gag E12K 5% 21% 42% 
Gag R76K 0 0 2% 
Gag Y79F 0 0 2% 
Gag T122A 4.8% 13% 26% 
Gag G123E 5.0% 13% 26% 
Gag V128del 100% 100% 100% 
Gag V370A 5% 0 1% 
Gag S373T 97% 98% 100% 
Gag R409K 3% 0 1% 
Gag S451T 100% 1.7% 0 
RT K65R 98% 0 0 
RT K103N 94% 0 0 
RT E138K 0 0 4% 
RT Y181C 100% 0 0 
RT M184I 100% 1.2% 21% 
RT M184V 0 0 79% 
replication-cycle drug susceptibility assay as measured by luciferase activity. Data displayed 
are fold difference in IC50 values of LPV in comparison to that of the assay reference strain, 
p8.9NSX. Error bars represent the standard error of the mean of at least three independent 
experiments performed in duplicate. 
 
Figure 3: The four amino acid MA mutant signature can be introduced into subtype B 
to reduce PI susceptibility. Site directed mutants were generated in the subtype B reference 
strain used in our assays. The V128del was also added as this deletion is present in HIV-1 
CRF02_AG. Data displayed are fold difference in IC50 values of LPV in comparison to that 
of the assay reference strain, p8.9NSX. Error bars represent the standard error of the mean of 
at least two independent experiments performed in duplicate. 
 
Figure 4: HIV-1 Gag cleavage efficiency in resistant versus susceptible isolates. A: 
Representative Western blot of virus containing supernatant at increasing drug dose, using a 
p24 antibody.  Size (kDa) is indicated on the left. In blue is the susceptible clone and red the 
resistant clone. B: Ratios of p24/p41 are presented in the graph below at increasing drug dose 
and data show mean (sd) of 2 independent experiments. Left bar is wild type and right bar is 
resistant virus. MA matrix (p17), CA capsid (p24), NC nucleocapsid, SP1 spacer peptide 1.  
 
Figure 5: Whole genome HIV haplotype reconstruction using target enriched NGS 
Illumina MiSeq data from each time point (baseline, VF1 and VF2), with maximum 
likelihood analysis and bootstrap support indicated using 1000 replicates. Labelled on the 
right side are the amino acids at positions Gag 122 and 123.  
 
Figure 6: Phylogenetic relationships between viral Gag-protease plasma derived 
sequences isolated at baseline (pre-PI) and at two failure time points (VF1 and VF2). 
Illustrated is a maximum likelihood tree with bootstrap support indicated at nodes. Outlier 
indicated is HXB2, a subtype B virus. VF1: viral failure 1 time point 41 months post 
initiation of protease inhibitor therapy; VF1: viral failure 2 time point 64 months post 
initiation of protease inhibitor therapy.  
 
Figure 7: A. Relationship between single round infectivity (RC) and LPV susceptibility 
(FC in IC50 compared to subtype B reference) for single round VSV-G pseudotyped 
viruses bearing patient derived gag-protease sequences. Error bars represent the standard 
error of the mean of at least two independent experiments performed in duplicate. B. 
Comparison of replication capacity over multiple rounds of infection for wild type Ba-L 
versus mutant bearing the 4 amino acid Gag Matrix signature T122A, G123E, 126del, 
127del. Error bars represent the standard error of the mean of technical replicates. Data are 
representative of two independent experiments.  
 
 
Supplementary Figure 1: Phenotypic drug susceptibility to lopinavir of virus isolates at 
baseline (pre second line) and after failure of second line PI based ART.  Susceptibility is 
expressed as fold change in IC50 as compared to a subtype B reference in a single round 
assay. Error bars represent the standard error of the mean of at least two independent 
experiments performed in duplicate. VF: viral failure 
 
Supplementary Figure 2: Impact of protease mutation M46V on LPV susceptibility. 
Mutations were made in both sensitive and resistant viruses. Data displayed are fold 
difference in IC50 values of LPV in comparison to that of the assay reference strain, 
p8.9NSX. Error bars represent the standard error of the mean of at least two independent 
experiments performed in duplicate. 
 
Supplementary Figure 3: Role of four amino acid sequence in p6 on LPV susceptibility. 
(A) amino acid sequence alignment showing in red positions in a gag-pro sequence that were 
mutated by site directed mutagenesis. (B) LPV fold change IC50 in a single round assay. 
Error bars represent SE of mean of at least two independent experiments. 
 
Supplementary Figure 4: Gag 126del and 127del mutations occurring with T122A and 
G123E did not have a significant resistance effect on susceptibility to the protease 
inhibitor Darunavir (A) The sequential introduction of mutations in the more susceptible 
clone (VF2 Clone 1) and (B), the reversion of the mutations in the resistant clone (VF2 Clone 
2). The sequences of the viral clones showing the amino acid changes introduced using 
standard site directed mutagenesis are shown in red. Full-length Gag-protease amplified from 
plasma samples as well as respective mutants were VSV-g pseudotyped, encoding luciferase 
were produced by co-transfection in 293T cells. PI susceptibility of pseudovirions was 
determined using a single replication-cycle drug susceptibility assay as measured by 
luciferase activity. Data displayed are fold difference in IC50 values of LPV in comparison to 
that of the assay reference strain, p8.9NSX. Error bars represent the standard error of the 
mean of at least two independent experiments performed in duplicate. 
 
Supplementary Figure 5: Role of single amino acid changes on LPV susceptibility. (A) 
amino acid sequence alignment showing in red positions in a gag-pro sequence that confers 
‘resistance’ mutated by site directed mutagenesis. (B) LPV fold change IC50 in a single 
round assay using luciferase as a read out. Error bars represent SE of mean of at least two 
independent experiments. 
 
Supplementary Table 1: genotypic consensus level sequence data derived from next 
generation sequencing for six individual participants failing protease inhibitor based second 
line ART before (BL) and after virological failure (VF).  Amino acids indicated represent 
differences from subtype B reference NL4.3. Amino acid positions in bold represent those 
previously associated with exposure to protease inhibitors. 
 
Supplementary Table 2: Representative raw IC50 data for sensitive (WT) and mutant (Mut2 
with T122A, G123E, S125del, H126del) clones. Two replicates (1 and 2) are indicated with 
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